Human Umbilical Cord Mesenchymal Stem Cell(Qilu Cell Therapy)

The main purpose of Phase Ia is to evaluate and determine the safety and tolerability of single-dose treatment for patients with acute-on-chronic liver failure. Secondary purpose: To evaluate the preliminary effectiveness of single-dose treatment for patients with acute-on-chronic liver failure; to provide a basis for the design of subsequent clinical trial doses. Exploratory study objectives: To explore the changes in HGF in patients with acute-on-chronic liver failure after single-dose treatment; to explore the changes in T lymphocyte typing in patients with acute-on-chronic liver failure after single-dose treatment; to explore the changes in humoral immune function in patients with acute-on-chronic liver failure after single-dose treatment. The main purpose of Phase Ib is to evaluate and determine the safety and tolerability of multiple-dose treatment for patients with acute-on-chronic liver failure. Secondary purpose: To evaluate the preliminary effectiveness of multiple-dose treatment for patients with acute-on-chronic liver failure; to provide a basis for the design of subsequent clinical trial doses. Exploratory study objectives: To explore the changes in HGF in patients with acute-on-chronic liver failure after multiple-dose treatment; to explore the changes in T lymphocyte typing in patients with acute-on-chronic liver failure after multiple-dose treatment; to explore the changes in humoral immune function in patients with acute-on-chronic liver failure after multiple-dose treatment. The main purpose of Phase II is to evaluate the preliminary effectiveness of treating patients with acute-on-chronic liver failure. Secondary study objective: To evaluate and determine the safety and tolerability of the treatment of patients with acute-on-chronic liver failure.

The main purpose of Phase Ia is to evaluate and determine the safety and tolerability of single-dose YFQLXB-UC01 injection in the treatment of patients with moderate to severe acute respiratory distress syndrome. Secondary purpose: to evaluate the preliminary effectiveness of a single dose in patients with moderate to severe acute respiratory distress syndrome; to provide a basis for the design of subsequent clinical trial doses. Exploratory study objectives: to explore the changes in peripheral blood cytokines in patients with moderate to severe acute respiratory distress syndrome after a single dose; to explore the changes in immune response indicators in patients with moderate to severe acute respiratory distress syndrome after a single dose; to explore the immunogenicity of patients with moderate to severe acute respiratory distress syndrome after a single dose. The main purpose of Phase Ib is to evaluate and determine the safety and tolerability of multiple doses in the treatment of patients with moderate to severe acute respiratory distress syndrome, and to determine the scope of clinical medication. Secondary purpose: to preliminarily explore the effectiveness of multiple doses in the treatment of moderate to severe acute respiratory distress syndrome. Purpose: To explore the changes in peripheral blood cytokines in patients with moderate to severe acute respiratory distress syndrome after multiple dosing; To explore the changes in immune response indicators in patients with moderate to severe acute respiratory distress syndrome after multiple dosing; To explore the immunogenicity in patients with moderate to severe acute respiratory distress syndrome after multiple dosing. The main purpose of Phase II: To evaluate the preliminary effectiveness of the treatment of moderate to severe acute respiratory distress syndrome. The secondary purpose: To evaluate the safety of the treatment of moderate to severe acute respiratory distress syndrome.